1 day chart
Inhibrx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of biologic therapeutic candidates in oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, INBRX-109, INBRX-105 and INBRX-106. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD) and acute Graft-versus -host-disease (aGvHD). INBRX-109 is an engineered tetravalent therapeutic candidate targeting death-receptor 5 (DR5), a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand or TRAIL receptor 2. INBRX-105 is a conditional tetravelent PD-L1 targeted 4-1BB agonist that is being investigated as a single agent and in combination with Keytruda in patients with locally advanced or metastatic solid tumors.
Buy US stocks in Australia starting with INBX. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in INBX
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.